ACP Aliath Bioventures II FCR fund has been registered

  • This fund specialises in investing in companies in the healthcare sector: biotechnology/biopharma and health technologies (digital health, medical devices and diagnostics).
  • Aliath Bioventures, part of the AltamarCAM group, is a healthcare sector impact investment platform.
  • This is AltamarCAM’s first Article 9 vehicle under the Sustainable Finance Disclosure Regulation (SFDR).

Madrid, 14 March 2023.- AltamarCAM Partners, a global asset manager focused on investing in private markets, has registered its new fund ACP Aliath Bioventures II FCR (ABV II) in the CNMV. This is AltamarCAM‘s second healthcare venture fund, investing predominantly in European companies, with a particular focus on Spain.

Aliath Bioventures is the healthcare sector impact investment platform of the AltamarCAM group. This name reflects both the strategic objective of the project, “Alliance for impact on health”, and the origin of the project, which was born from the partnership between AltamarCAM and the Alta Life Sciences team.

With this fund, AltamarCAM continues to invest in the healthcare sector with a combined objective: to obtain attractive financial returns for investors while also generating a positive social impact through the investments.

Accordingly, ABV II has been registered as an Article 9 fund under the Sustainable Finance Disclosure Regulation (SFDR). The sustainability profiles of its portfolio companies will therefore be an essential part of its strategy, and to this end the team has designed specific investment and monitoring processes to better assess the sustainability of underlying companies.

The fund is also AltamarCAM’s first impact vehicle. A series of quantitative impact indicators have been identified, new reporting processes have been developed and the fund’s carried interest has been aligned with its impact objectives.

Aliath Bioventures has a highly experienced team with complementary profiles, led by Montserrat Vendrell, Scott Moonly and José María Fernández, who are advised by renowned professionals from the scientific world and the healthcare venture capital industry. Furthermore, as part of the AltamarCAM group, Aliath has access to a complete platform of support functions including legal, ESG, finance, compliance, investor relations and technology.

ABV II will follow the strategy of its predecessor fund Alta Life Sciences Spain I FCR and invest in European companies, with a weighting towards Spain, and the possibility to make some investments outside of Europe.  Its investments will be focused on companies operating in biotechnology and biopharma, or related to health technologies (digital health, medical devices or diagnostics). Their investment philosophy is active, through positions on the Boards of Directors of the companies in which they invest.

According to José Luis Molina, CEO of AltamarCAM, “with Aliath Bioventures we want to generate value for our investors while also improving people’s health. We are very lucky to have a great team that has designed a very innovative investment product with an impact and sustainability strategy to invest in disruptive and efficient social impact solutions.

According to Montserrat Vendrell, Partner of Aliath Bioventures, “the healthcare sector is a global business going through an extraordinary phase of disruptive innovation and offers great opportunities for investment and impact on the health of individuals. For our new fund we have developed new tools and indicators through which we will measure our contribution to sustainability.

Leave a Reply